# US 2014/0194343 A1 · Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194343 A1
- Document ID: US20140194343A1
- Status: Published application
- Kind: A1
- Application number: 14/116,039
- Filed: 2012-05-09
- Published: 2014-07-10
- Earliest claimed: 2011-05-13
- Assignees: The University of Tokyo
- Inventors: Yoichiro Iwakura; Masanori Murayama; Harumichi Ishigame; Shigeru Kakuta
- Web page: https://patentgrep.com/patent/US20140194343A1

## CPC

- C07K 14/47: from mammals
- A61K 38/1709: {from mammals}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

[Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. [Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.

## Claims

### Claim 1

A method of treating or preventing an autoimmune disease in a mammalian subject in need thereof, comprising administering to said subject a therapeutically effective amount of CTRP6.

### Claim 2 (depends on 1)

The method of claim 1 wherein said CTRP6 comprises an amino acid sequence represented by
a. human CTRP6 (SEQ ID NO: 1) or
b. mouse CTRP6 (SEQ ID NO: 2);
or is
c. a protein having at least 80% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2 and activity to suppress complement activation, or
d. a protein comprising an amino acid sequence in which one or several amino acids have been deleted, substituted, or added in SEQ ID NO: 1 or SEQ ID NO: 2, and having activity to suppress complement activation.

### Claim 3 (depends on 1)

The method of claim 1 wherein the autoimmune disease is an inflammatory disorder selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, type 1 diabetes, vitiligo, systemic lupus erythematosus, biliary cirrhosis, uveitis, vesicular pemphigoid, Graves' ophthalmopathy, multiple sclerosis, lupus, fibromyalgia, sepsis, septic shock, endotoxin shock, gram-negative bacterial sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammation, inflammatory bowel disease, Crohn's disease, psoriasis, eczema, ulcerative colitis, pancreatic fibrosis, hepatic fibrosis, acute and chronic nephropathy, irritable bowel syndrome, fever, restenosis, cerebral malaria, ischemic injury, nerve damage, Alzheimer's disease, Huntington's disease, Parkinson's disease, acute and chronic pain, allergic rhinitis, allergic conjunctivitis, chronic heart failure, acute coronary syndrome, and graft-versus-host reaction.

### Claim 4 (depends on 1)

The method of claim 1 wherein the autoimmune disease is a disease related to the complement alternative pathway.

### Claim 5 (depends on 1)

The method of claim 1 wherein the autoimmune disease is rheumatoid arthritis or type 1 diabetes.